Ushbu ishga iqtibos qilgan ishlar

5 ta ish

Ish: A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

1. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

   S. Moe, M. L. Rekart, D. Hernandez +9

   MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20231 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.281628

2. Introducing BPaL: Experiences from countries supported under the LIFT-TB project

   D. F. Wares, M. Mbenga, Veriko Mirtskhulava +19

   MaqolaTuberculosis Research and EpidemiologyPLoS ONE20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.000471

3. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

   Ilaria Motta, Martina Cusinato, Andrew Ludman +15

   MaqolaCardiac electrophysiology and arrhythmiasAntimicrobial Agents and Chemotherapy20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.000869

4. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

   Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

   MaqolaTuberculosis Research and EpidemiologyClinical Infectious Diseases20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000230

5. Quality of life outcomes and patient-reported experiences in a randomised controlled trial for rifampicin-resistant TB (PRACTECAL-PRO): a mixed-methods study

   Karen Lowton, Beverley Stringer, M. Cusinato +7

   MaqolaTuberculosis Research and EpidemiologyIJTLD OPEN20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.016746